1
|
Vitória Minzoni de Souza Iacia M, Eduarda Ferraz Mendes M, Cristiny de Oliveira Vieira K, Cristine Marques Ruiz G, José Leopoldo Constantino C, da Silva Martin C, Eloizo Job A, Alborghetti Nai G, Kretli Winkelstroter Eller L. Evaluation of curcumin nanoemulsion effect to prevent intestinal damage. Int J Pharm 2024; 650:123683. [PMID: 38092264 DOI: 10.1016/j.ijpharm.2023.123683] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/05/2023] [Revised: 11/20/2023] [Accepted: 12/05/2023] [Indexed: 12/26/2023]
Abstract
Curcumin has gained great prominence for the prevention and treatment of inflammatory bowel disease. However, studies have reported the low bioavailability of orally administered curcumin. This work aimed to evaluate the characteristics, stability and effects of a curcumin-carrying nanoemulsion in preventing intestinal damage induced by indomethacin. Nanoemulsions containing curcumin were prepared by spontaneous emulsification method and it was characterized by dynamic light scattering (DLS), zeta potential and the morphology was evaluated by scanning electron microscopy (SEM). Its stability was tested under different conditions of pH, temperature at 0, 7, 14, 21 and 28 days. In animal experimentation, 36 male mice of the Mus musculus lineage (C57BL/6) were used. The intestinal inflammation was evaluated based on macroscopic, histopathological and metagenomic analysis. It was found a stable nanoemulsion with a size of 409.8 nm, polydispersion index (PDI) of 0.132 and zeta potential of -18.8 mV. However, these lost charge in pH2, showing instability in acidic media (p < 0.05). In animal experiments, the nanoemulsion did not significantly improve intestinal inflammation. However, the group treated with curcumin nanoemulsion showed a higher relative abundance of the genus Lactobacillus (p < 0.05). In conclusion, the curcumin nanoemulsion was relevant in the modulation of the intestinal microbiota.
Collapse
Affiliation(s)
| | | | | | - Gilia Cristine Marques Ruiz
- Department of Physics, Faculty of Science and Technology, Universidade Estadual Paulista, FCT/UNESP, Presidente Prudente, SP, Brazil
| | - Carlos José Leopoldo Constantino
- Department of Physics, Faculty of Science and Technology, Universidade Estadual Paulista, FCT/UNESP, Presidente Prudente, SP, Brazil
| | - Cibely da Silva Martin
- Department of Physics, Faculty of Science and Technology, Universidade Estadual Paulista, FCT/UNESP, Presidente Prudente, SP, Brazil
| | - Aldo Eloizo Job
- Department of Physics, Faculty of Science and Technology, Universidade Estadual Paulista, FCT/UNESP, Presidente Prudente, SP, Brazil
| | - Gisele Alborghetti Nai
- Master's in Health Sciences - Universidade do Oeste Paulista/UNOESTE, Presidente Prudente, SP, Brazil; Program of Animal Science - Universidade do Oeste Paulista/UNOESTE, Presidente Prudente, Brazil
| | - Lizziane Kretli Winkelstroter Eller
- Faculty of Health Sciences - Universidade do Oeste Paulista/UNOESTE, Presidente Prudente, SP, Brazil; Master's in Health Sciences - Universidade do Oeste Paulista/UNOESTE, Presidente Prudente, SP, Brazil; Program of Animal Science - Universidade do Oeste Paulista/UNOESTE, Presidente Prudente, Brazil.
| |
Collapse
|
2
|
Beiranvand M. A review of the biological and pharmacological activities of mesalazine or 5-aminosalicylic acid (5-ASA): an anti-ulcer and anti-oxidant drug. Inflammopharmacology 2021; 29:1279-1290. [PMID: 34410540 DOI: 10.1007/s10787-021-00856-1] [Citation(s) in RCA: 9] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/23/2021] [Accepted: 07/24/2021] [Indexed: 11/28/2022]
Abstract
Mesalazine, also known as 5-aminosalicylic acid (5-ASA), is a synthetic drug from the family of nonsteroidal anti-inflammatory drugs (NSAIDs) used for inflammatory diseases of the gastrointestinal tract. However, 5-ASA has also been used for various other diseases due to its pharmacological effects, but they are usually scattered across various publications, which may limit further research and clinical use of this drug. This review is a summary of published information on the biological and pharmacological effects of 5-ASA with the aim of identifying its anti-oxidant role and medicinal use. 5-ASA data have been collected from 1987 to February 2021 using major databases such as Web of Science, PubMed, Elsevier, Wiley Online Library, Springer, Google Scholar, etc. According to research, the pharmacological and biological effects of 5-ASA include treatment of inflammatory bowel disease, and anti-oxidant, anti-inflammatory, antibacterial, antifungal, anticancer, anti-amyloid, gastric protection (gastroprotective), and antidiverticulosis properties. Numerous pharmacological studies have shown that 5-ASA is an anti-oxidant and anti-ulcer compound with high therapeutic potential that, if the appropriate dose is discovered, its chemical structure changes and its effectiveness is optimized, 5-ASA has been used experimentally for other diseases.
Collapse
Affiliation(s)
- Mohammad Beiranvand
- Department of Biology, Faculty of Basic Sciences, Lorestan University, Khorramabad, Iran.
| |
Collapse
|
3
|
Jung ES, Jang HJ, Hong EM, Lim HL, Lee SP, Kae SH, Lee J. The Protective Effect of 5-Aminosalicylic Acid Against Non-Steroidal Anti-Inflammatory Drug-Induced Injury Through Free Radical Scavenging in Small Intestinal Epithelial Cells. ACTA ACUST UNITED AC 2020; 56:medicina56100515. [PMID: 33019698 PMCID: PMC7600857 DOI: 10.3390/medicina56100515] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/27/2020] [Revised: 09/23/2020] [Accepted: 09/28/2020] [Indexed: 12/22/2022]
Abstract
Background and objectives: Non-steroidal anti-inflammatory drugs (NSAIDs) have been among the major causes of small intestinal injury in clinical practice. As such, the current study investigated the protective effect of 5-aminosalicylic acid (5-ASA) against an NSAID-induced small intestinal injury. Materials and Methods: IEC-6 cells were treated with various concentrations of indomethacin with or without 5-ASA in a serum-free medium, after which an 3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Dromide (MTT) assay, a cell apoptosis assay, a caspase-3 activity assay, a reactive oxygen species (ROS) content and Superoxide dismutase 2 (SOD2) activity measurement, a Western blotting for occludin and zonula occludens-1 (ZO-1) and a wound healing assay were conducted. Results: 5-ASA ameliorated indomethacin-induced cell apoptosis and an increase in the intracellular ROS content while augmenting the indomethacin-induced suppression of SOD2 activity in IEC-6 cells. Moreover, 5-ASA reversed the indomethacin-induced attenuation of occludin and ZO-1 expression and promoted faster wound healing effects in IEC-6 cells following an indomethacin-induced injury. Conclusions: Our results suggested that 5-ASA protects small intestinal cells against an NSAID-induced small intestinal injury by scavenging free radicals. Therefore, 5-ASA could be a potential treatment for an NSAID-induced small intestinal injury.
Collapse
|